Literature DB >> 14507281

The role of toxicology assessment in transfusion medicine.

Vic Ciaravino1, Tim McCullough, George Cimino.   

Abstract

Mesh：

Year:  2003        PMID： 14507281     DOI： 10.1046/j.1537-2995.2003.00544.x

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  7 in total

Review 1.  Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies.

Authors:  Kathryn E Webert; Christine M Cserti; Judy Hannon; Yulia Lin; Katerina Pavenski; Jacob M Pendergrast; Morris A Blajchman
Journal:  Transfus Med Rev       Date:  2008-01

Review 2.  Pathogen inactivation technologies for cellular blood components: an update.

Authors:  Peter Schlenke
Journal:  Transfus Med Hemother       Date:  2014-07-21       Impact factor: 3.747

3.  Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland.

Authors:  Markus Jutzi; Behrouz Mansouri Taleghani; Morven Rueesch; Lorenz Amsler; Andreas Buser
Journal:  Transfus Med Hemother       Date:  2018-05-23       Impact factor: 3.747

4.  How do you… decide which platelet bacterial risk mitigation strategy to select for your hospital-based transfusion service?

Authors:  Wen Lu; Meghan Delaney; Willy A Flegel; Paul Ness; Nora Ratcliffe; Darrell J Triulzi; Mark H Yazer; Alyssa Ziman; Nancy M Dunbar
Journal:  Transfusion       Date:  2020-02-06       Impact factor: 3.337

Review 5.  Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Authors:  Giovanni Di Minno; David Navarro; Carlo Federico Perno; Mariana Canaro; Lutz Gürtler; James W Ironside; Hermann Eichler; Andreas Tiede
Journal:  Ann Hematol       Date:  2017-06-18       Impact factor: 3.673

Review 6.  Pathogen inactivation techniques.

Authors:  J P R Pelletier; S Transue; E L Snyder
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

7.  The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates.

Authors:  Ouada Nebie; David Devos; Valérie Vingtdeux; Lassina Barro; Jean-Christophe Devedjian; Aurélie Jonneaux; Ming-Li Chou; Régis Bordet; Luc Buée; Folke Knutson; David Blum; Thierry Burnouf
Journal:  J Biomed Sci       Date:  2019-10-31       Impact factor: 8.410
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.